🇺🇸 FDA
Patent

US 11548951

Compositions and methods for treatment of thyroid eye disease

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11548951 (Compositions and methods for treatment of thyroid eye disease) held by Viridian Therapeutics, Inc. expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Viridian Therapeutics, Inc.
Grant date
Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K9/0019